Korean biopharma companies to collaborate with Indian firms CEOs of Korean and Indian firms to have meeting this week
Translated by Kim So-in 공개 2021-07-15 08:00:15
이 기사는 2021년 07월 15일 07:52 thebell 에 표출된 기사입니다.
South Korean biopharmaceutical companies will collaborate with Indian companies to build a global supply chain.The Indian Embassy in Seoul and Association of Biotechnology Led Enterprises (ABLE) will hold an online meeting with CEOs of biopharmaceutical companies on Friday. The hosts selected and invited leading companies from Korea and India in four sectors: vaccines, biopharmaceuticals, cell and gene therapy products, and molecular diagnostics and genomic analysis.
India's pharmaceutical market, which is now worth $43 billion, is growing at an average annual rate of 9.5%.
In the vaccine sector, SK Bioscience has been invited from Korea while Wockhardt and Dr.Reddy's Laboratories were chosen among Indian pharmaceutical companies. Headquartered in Mumbai, Wockhardt has produced and supplied U.K.-based AstraZeneca's Covid-19 vaccine. Dr.Reddy's Laboratories acquired Wockhardt's generics division in five Asian countries last year.
In the biopharmaceutical sector, LG Chem and Biocon Biologics, a subsidiary of Biocon, have been invited to the event. LG Chem has biosimilars for autoimmune diseases such as adalimumab BS MA, referencing the drug Humira, and Eucept, an Enbrel biosilimar.
Daewoong Pharma and Stempeutics will seek opportunities to collaborate in the cell and gene therapy products sector. Daewoong Pharma entered the cell therapy contract development and manufacturing organization (CDMO) business this year after receiving a manufacturing license for advanced biopharmaceuticals from the Ministry of Food and Drug Safety.
Stempeutics is a biotech firm specialized in mesenchymal stem cell technology. The company received the green light from the Drug Controller General of India last year to launch its Stempeucel therapy to treat critical limb ischemia (CLI) due to Buerger’s disease and atherosclerotic peripheral arterial disease.
LabGenomics and Syngene International will join hands among diagnostic firms. The two companies will reportedly review the possibility of producing polymerase chain reaction (PCR) diagnostic kits and immunology diagnostic kits in India. They are also considering exchanging technology related to next-generation sequencing (NGS) services.
LabGenomics, a company specializing in molecular diagnostics, recorded best financial performance ever in 2020 thanks to exports of Covid-19 related products. India has the strongest demand for LabGenomics’ diagnostic kits. Syngene International focuses on new drug development.
“Korea is the country which stands out in research and development, while India has a strong manufacturing ecosystem and protects intellectual property rights,” said an industry source. “Domestic companies entering the global market will have competitiveness if they cooperate with Indian companies.” (Reporting by A-ran Sim)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- ICTK, 일반청약 경쟁률 1108대1 '증거금 5.4조'
- [Company Watch]인적분할 나선 서진시스템, 신설법인에 ESS사업 배정
- 골리앗에 맞선 이오플로우, '인슐렛' 소송전 청신호
- [Red & Blue]지투파워, 한수원 체코 원전 수주시 납품 기대감
- 공모 시총 3000억 육박한 ICTK, 기관투자가 '웃음꽃'
- [CVC 톺아보기]'카카오' 계열 편입 '기폭제', 그룹 지원 속 폭풍 성장
- 두산건설, '반도체 메가 클러스터' 수혜 단지 분양
- [코스닥 리빌딩 리포트]1000억 CB 공수표 날린 퀀타피아, 공개매각 추진
- 올리패스 잠재 대주주 사내이사로…수익성 확보 총력
- '대유타워 매각' 대유위니아, 새 원매자 찾기 시동